These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9030597)

  • 1. Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle.
    Richter M; Schleithoff L; Deufel T; Lehmann-Horn F; Herrmann-Frank A
    J Biol Chem; 1997 Feb; 272(8):5256-60. PubMed ID: 9030597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1).
    Du GG; Oyamada H; Khanna VK; MacLennan DH
    Biochem J; 2001 Nov; 360(Pt 1):97-105. PubMed ID: 11695996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The point mutation Arg615-->Cys in the Ca2+ release channel of skeletal sarcoplasmic reticulum is responsible for hypersensitivity to caffeine and halothane in malignant hyperthermia.
    Otsu K; Nishida K; Kimura Y; Kuzuya T; Hori M; Kamada T; Tada M
    J Biol Chem; 1994 Apr; 269(13):9413-5. PubMed ID: 7511586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation.
    Wehner M; Rueffert H; Koenig F; Neuhaus J; Olthoff D
    Clin Genet; 2002 Aug; 62(2):135-46. PubMed ID: 12220451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calmodulin sensitivity of the sarcoplasmic reticulum ryanodine receptor from normal and malignant-hyperthermia-susceptible muscle.
    O'Driscoll S; McCarthy TV; Eichinger HM; Erhardt W; Lehmann-Horn F; Herrmann-Frank A
    Biochem J; 1996 Oct; 319 ( Pt 2)(Pt 2):421-6. PubMed ID: 8912676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.
    Tong J; Oyamada H; Demaurex N; Grinstein S; McCarthy TV; MacLennan DH
    J Biol Chem; 1997 Oct; 272(42):26332-9. PubMed ID: 9334205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees.
    Keating KE; Quane KA; Manning BM; Lehane M; Hartung E; Censier K; Urwyler A; Klausnitzer M; Muller CR; Heffron JJ
    Hum Mol Genet; 1994 Oct; 3(10):1855-8. PubMed ID: 7849712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of propofol on Ca2+ regulation by malignant hyperthermia-susceptible muscle membranes.
    Fruen BR; Mickelson JR; Roghair TJ; Litterer LA; Louis CF
    Anesthesiology; 1995 May; 82(5):1274-82. PubMed ID: 7741303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala.
    Wehner M; Rueffert H; Koenig F; Olthoff D
    Genet Test; 2003; 7(3):203-11. PubMed ID: 14641996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test.
    Brandt A; Schleithoff L; Jurkat-Rott K; Klingler W; Baur C; Lehmann-Horn F
    Hum Mol Genet; 1999 Oct; 8(11):2055-62. PubMed ID: 10484775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia.
    Treves S; Larini F; Menegazzi P; Steinberg TH; Koval M; Vilsen B; Andersen JP; Zorzato F
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):661-5. PubMed ID: 8053891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity of the ryanodine receptor to halothane-induced oligomerization in malignant hyperthermia-susceptible human skeletal muscle.
    Glover L; Heffron JJ; Ohlendieck K
    J Appl Physiol (1985); 2004 Jan; 96(1):11-8. PubMed ID: 12959958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility.
    Roesl C; Sato K; Schiemann A; Pollock N; Stowell KM
    Cell Calcium; 2014 Sep; 56(3):195-201. PubMed ID: 25086907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.
    Keating KE; Giblin L; Lynch PJ; Quane KA; Lehane M; Heffron JJ; McCarthy TV
    J Med Genet; 1997 Apr; 34(4):291-6. PubMed ID: 9138151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes.
    Robinson RL; Brooks C; Brown SL; Ellis FR; Halsall PJ; Quinnell RJ; Shaw MA; Hopkins PM
    Hum Mutat; 2002 Aug; 20(2):88-97. PubMed ID: 12124989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A search for three known RYR1 gene mutations in 41 Swedish families with predisposition to malignant hyperthermia.
    Fagerlund TH; Islander G; Twetman ER; Berg K
    Clin Genet; 1995 Jul; 48(1):12-6. PubMed ID: 7586638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Search for three known mutations in the RYR1 gene in 48 Danish families with malignant hyperthermia.
    Fagerlund T; Ording H; Bendixen D; Berg K
    Clin Genet; 1994 Dec; 46(6):401-4. PubMed ID: 7889656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia.
    O'Brien RO; Taske NL; Hansbro PM; Matthaei KI; Hogan SP; Denborough MA; Foster PS
    J Med Genet; 1995 Nov; 32(11):913-4. PubMed ID: 8592342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.